Alterity Therapeutics Limited - Sponsored ADR

ATHE Healthcare Biotechnology

Revenue growth for five consecutive years; insiders bought in the last twelve months.

2.62 0.10 −3.68%
Market cap
$52.0M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
4/9
Altman Z
2.15
Beneish M
30.19
Dividend safety
n/a
Older periods Dec '24 Jun '25 Dec '25 Jun '26
Current Ratio

+8 more quarters

3.84 12.98 21.98 14.52
Net Debt/EBITDA
0.00 0.00 0.00 0.00
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
0.00 0.00 0.00 0.00
Capex/Depreciation
0.00 0.00 0.00 0.00
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% — 0.00% —
Free Cash Flow per Share
0.00 0.00 0.00 0.00
Cash per Share
0.00 0.00 0.00 0.00
Shareholders Equity per Share
0.00 0.00 0.00 0.00
Book value per Share
0.00 0.00 0.00 0.00
Free Cash Flow
(5.44) (7.42) (6.97) (15.29)
Working Capital
5.02 27.42 35.61 28.96
Capital Expenditures
— 0.00 — 0.00
Net Current Asset Value
5.00 27.36 35.57 28.87
Other line items
Quick Ratio
3.76 10.50 21.68 14.26
Operating CF per Share
0.00 0.00 0.00 0.00
Capex per Share
— 0.00 — 0.00
Average Receivables
4.18 4.19 4.20 3.94
Average Payables
2.13 2.02 1.71 2.20
Average Assets
14.41 24.10 25.92 21.92
Average Common Equity
11.78 21.41 23.56 19.02
Capex to Sales
— 0.00 — 0.00

Fold the line items

Columns are period end dates